Although a number of genomic and proteomic studies have been conducted over the years to elucidate the effect of KRAS mutations on tumor cells [7, 17, 20] in reality, the true nature of the KRAS signaling architecture in vivo within the complex tumor host microenvironment has so far been only marginally explored. This evidence concerns the gene KRAS and neoplasm.